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ABSTRACT
Secondary preventive drug treatment in patients aged
≥60 years with a history of myocardial infarction was
investigated for age-dependent differences in time
trends. Sixteen general practices in the Netherlands
participated. Preventive treatment with at least three
of four drugs (antithrombotics, statins, beta-blockers,
and/or angiotensin-converting enzyme inhibitors)
increased significantly over time in all three age strata
of older patients. Although the greatest relative
increase (2.2 times greater) took place in patients aged
≥80 years, these patients consistently had most room
for improvement.
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INTRODUCTION
The incidence of myocardial infarction (MI) increases
with age, and the prognosis worsens.1 Secondary
prevention following MI involves treatment with a
combination of four preventive drugs which is
believed to result in a cumulative risk reduction of
about 75%, regardless of age.2 The current study
investigated time trends (2000–2007) in preventive
drug treatment in community-dwelling patients aged
≥60 years with a history of MI.
METHOD
At three points in time, in the years 2000, 2004, and
2007 all registered and living patients aged ≥60 years
with the diagnosis ‘myocardial infarction’ confirmed in
their medical records (code K75, International
Classification of Primary Care) were selected from the
Registration Network of General Practices associated
with Leiden University (RNUH-LEO), a database of
electronic medical records of all patients listed in 16
regular general practices in the western part of the
Netherlands. Data extractions were cross-sectional,
and patients could reappear in consecutive samples.
Complete records of drug prescriptions during the
year preceding the above-mentioned three time
points were extracted. Availability (in days) of
antithrombotics (Anatomical Therapeutic Chemical
codes B01AA* or B01AC*), statins (C10AA*), beta-
blockers (C07*), and angiotensin-converting enzyme
(ACE) inhibitors (C09A* or C09B*) in the preceding
year was calculated by dividing the total number of
prescribed pills in a year by the prescribed daily dose.
If this resulted in 183 or more days per year of pill
availability (corresponding to more than 50% of the
year), preventive treatment with this specific drug was
arbitrarily considered sufficient. If the time since last
MI was less than 1 year, the required number of days
of pill availability was proportionally adjusted. Per
drug category, and within strata by age (60–69,
70–79, and ≥80 years), proportions of patients with
sufficient treatment were assessed. Finally, per age
stratum, overall sufficient preventive treatment was
measured, defined as sufficient treatment with at
least three of four categories of drugs.
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RESULTS
The population under observation (all patients aged
≥60 years) in 2000 was 3655 (13.1% of all registered
patients), increasing to 4419 (14.9% of all registered
patients) in 2004, and 5913 (16.7% of all registered
patients) in 2007. The proportions of post-MI patients
were 6.3% (232/3655), 6.0% (266/4419), and 5.1%
(302/5913) respectively.
Characteristics of all post-MI patients at the three
time points, as well as overall preventive drug
treatment (at least three of four drugs) are summarised
in Table 1. At all time points, more than 80% of all
post-MI patients were treated with antithrombotics,
while treatment with beta-blockers and ACE inhibitors
showed a moderate increase over time. The most
obvious increase in treatment over time was observed
with statins. Overall, sufficient preventive treatment
doubled over time, from 33% of all post-MI patients in
2000 to 60% of patients in 2007.
Table 2 presents preventive drug treatment in strata
by age at the three time points. In all age groups,
overall sufficient preventive treatment increased over
time. The relative increase between 2000 and 2007
was highest in patients aged ≥80 years (2.2 times
greater), although by 2007 still only half of these
patients received sufficient preventive drug treatment.
Regarding specific drugs, treatment with
antithrombotics was high in all age groups at all time
points, whereas preventive treatment with all other
drugs, mainly statins, increased over time. In the age
group 60–69 years, treatment with ACE inhibitors
doubled between 2000 and 2007.
DISCUSSION
Summary of main findings
This study shows that sufficient preventive drug
treatment in patients aged ≥60 years with a history of
MI doubled over a recent 7-year period. In all age
groups, considerable improvements were observed,
with the greatest relative increase in patients aged
≥80 years. However, absolute differences in
treatment between age groups were equally
remarkable: in 2007, more than two-thirds of all
patients aged 60–69 years were on sufficient
preventive drug treatment, as opposed to half of the
patients aged ≥80 years. The oldest old patients
therefore still have the most room for improvement.
The observed increase of preventive drug
treatment over time can partly be explained by
changes in medical guidelines, recommending an
increasing number of preventive drugs over time, as
evidence of their effectiveness became available.
Furthermore, guidelines have abandoned upper age
limits.3 Together, these changes may also explain the
continual lagging behind of preventive drug treatment
in the oldest old.
How this fits in
Secondary preventive drug treatment following myocardial infarction (MI) in
older patients has been reported as incomplete, which is in contravention of
current guidelines. Although preventive drug treatment in post-MI patients
aged ≥60 years and over showed a steep increase in recent years, particularly
in the oldest old (≥80 years), it is advised that GPs periodically review the
preventive drug regimens of their (older) post-MI patients to ensure
optimisation with current guidelines.
2000, n = 232 2004, n = 266 2007, n = 302
Proportion of males 70 (64 to 76) 74 (69 to 79) 72 (67 to 77)
Age group, years
60–69 43 (36 to 49) 44 (39 to 50) 40 (35 to 46)
70–79 34 (29 to 41) 34 (29 to 40) 36 (31 to 41)
≥80 23 (18 to 29) 21 (17 to 27) 24 (19 to 29)
Preventive drug treatmentb
Antithrombotics 81 (76 to 86) 85 (81 to 89) 88 (84 to 91)
Statins 44 (38 to 50) 67 (61 to 72) 71 (65 to 76)
Beta-blockers 40 (34 to 46) 52 (46 to 58) 58 (52 to 63)
ACE-inhibitors 30 (25 to 36) 36 (31 to 42) 47 (41 to 52)
3 to 4 drugs 33 (27 to 39) 52 (46 to 58) 60 (54 to 65)
aData presented as percentages (95% CIs). bPills available for more than 50% of days in
preceding year. ACE = angiotensin-converting enzyme.
Table 1. Characteristics and overall preventive drug
treatment in patients aged ≥60 years with a history of
myocardial infarction (total n = 800), at three time pointsa
2000, 2004, 2007,
total n = 232 total n = 266 total n = 302
Age 60–69 years n = 99 n = 118 n = 122
3–4 drugs 38 (29 to 48) 59 (50 to 68) 70 (62 to 78)
Type of drug
Antithrombotics 78 (69 to 85) 83 (75 to 89) 89 (83 to 94)
Statins 56 (46 to 65) 78 (70 to 84) 77 (69 to 84)
Beta-blockers 42 (33 to 52) 53 (44 to 62) 63 (54 to 71)
ACE inhibitors 28 (20 to 38) 38 (30 to 47) 57 (48 to 65)
Age 70–79 years n = 80 n = 91 n = 108
3–4 drugs 34 (24 to 45) 49 (39 to 60) 55 (45 to 64)
Type of drug
Antithrombotics 85 (76 to 91) 86 (77 to 91) 86 (78 to 91)
Statins 46 (36 to 57) 67 (57 to 76) 73 (64 to 81)
Beta-blockers 35 (25 to 46) 51 (40 to 61) 56 (47 to 65)
ACE inhibitors 35 (25 to 46) 30 (21 to 40) 39 (30 to 48)
Age ≥80 years n = 53 n = 57 n = 72
3–4 drugs 23 (13 to 36) 40 (29 to 53) 50 (39 to 61)
Type of drug
Antithrombotics 83 (71 to 91) 89 (79 to 95) 89 (80 to 94)
Statins 19 (11 to 31) 44 (32 to 57) 57 (45 to 68)
Beta-blockers 42 (29 to 55) 51 (38 to 63) 50 (39 to 61)
ACE inhibitors 28 (18 to 42) 42 (30 to 55) 42 (31 to 53)
aPills available for more than 50% of days in preceding year. bData presented as
percentages (95% CIs). ACE = angiotensin-converting enzyme.
Table 2. Preventive drug treatmenta in patients aged
≥60 years with a history of myocardial infarction, depending
on age group, at three time points.b
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Strengths and limitations of the study
It could be seen as a limitation that it was not
possible to adjust the results for possible
confounders and comorbidities. However, as this
was consistently so over time, it is unlikely that the
nature of the observed time trends would have been
much different.
Comparison with existing literature
These data are roughly in line with existing relevant
literature.4–6 Surprisingly, a study from Aberdeen, UK,
yielded a seemingly opposite result, with the oldest
patients being more likely to receive ‘at least one out
of four secondary preventive drugs’.6 As this latter
definition for sufficient secondary prevention differs
substantially from the one used in the present study,
the findings of these two studies cannot
straightforwardly be compared.
Implications for clinical practice
The study findings suggest that, although over the
last 7 years the oldest old post-MI patients are
catching up with their younger counterparts, they still
have most room for improvement. On referring these
patients back to primary care, the medical specialist
should therefore recommend that GPs periodically
review patients’ preventive drug regimens to ensure
adherence with the latest guidelines.
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